Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in the metadata) for the month of October 2018. The registrant is a foreign private issuer incorporated in Belgium, with its principal executive office in Mechelen. The filing serves to incorporate by reference a press release dated October 24, 2018 (Exhibit 99.1), regarding a material event.
Financial Metrics
The filing text does not provide specific financial data. No values are disclosed for revenue, profit, cash flow, margins, debt, or liquidity within this specific Form 6-K document. The filing acts solely as a conduit for the attached press release.
Material Changes
The document reports the issuance of a press release on October 24, 2018, as the material event. The text does not detail the specific content of the press release or quantify any material changes versus prior periods, other than noting the inclusion of a quote by Mr. Onno van de Stolpe in the exhibit.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not described in the body of this filing. The filing states that the information in Exhibit 99.1 (the press release) is incorporated by reference into the Company's Registration Statements on Forms F-3 and S-8. Specific details regarding these topics must be found in the attached Exhibit 99.1, which is not included in the provided text.
Key Facts for Investor Verification
- Verify the actual content of the October 24, 2018 press release (Exhibit 99.1) to understand the material event triggering this filing.
- Confirm the identity of the registrant as Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" label in the request metadata.
- Review the referenced Registration Statements (Forms F-3 and S-8) for broader context on the company's capital structure and ongoing disclosures.
- Note that this filing contains no standalone financial metrics or quantitative performance data.